Liver cancer
Conditions
Interventions
Surgical modalities Group A:ICG fluorescence-guided partial hepatectomy
Surgical modalities Group B:Anatomic partial hepatectomy
Sponsors
the first affiliated hospital of Chongqing medical university
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1 Patients with hepatocellular carcinoma who underwent pathology or abdominal enhanced CT/MRI and met the definition of primary liver cancer diagnosis and treatment standard of China 2022 edition; 2 Measurable lesions that meet the RECIST criteria; 3 Resectable defined as primary liver cancer of CNLC stage Ia, Ib, or IIa with good liver reserve function, and the tumor is not located in the central part of the liver and far away from large blood vessels, bile ducts, hepatic hilar and other unresectable areas. Other physical conditions: patients are assessed to have general safety conditions for surgery, including good cardiopulmonary function, no serious comorbidities and no contraindications. 4 Previously untreated patients; 5 Liver function Child-Pugh grade A and Eastern Cooperative Oncology Group Physical Status Activity (ECOGPS) score <2; 6 Informed understanding of all treatment options and good compliance with outpatient follow-up, with complete follow-up data.
Exclusion criteria
Exclusion criteria: 1 Patients with combined organic lesions of important organs such as heart, brain and kidney or accompanied by other malignant tumors; 2 Patients with other treatment modalities of previous previous hepatocellular carcinoma; 3 Liver function failure (liver function Child-Pugh classification B/C); 4 Patients with incomplete clinical data; 5 Patients with poor compliance, pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) for both surgical modalities;Surgical time in patients with both surgical modalities;disease-free survival (DFS) for both surgical modalities;bleeding in patients with both surgical modalities; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver and kidney function;complication;blood routine;coagulation function;tumor markers; | — |
Countries
China
Contacts
Public ContactDu Chengyou
the first affiliated hospital of Chongqing medical university
Outcome results
None listed